Sarah Wolf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sarah Wolf has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Ingrid Zechmeister-Koss
HTA Austria—Austrian Institute for Health Technology Assessment GmbH, Austria
4 shared publicationsClaudia Wild
HTA Austria—Austrian Institute for Health Technology Assessment GmbH (Former: Ludwig Boltzmann Institute for HTA) , Vienna
3 shared publicationsBrian Yuen Yau Wong
Andrews University, Berrien Springs, MI
2 shared publicationsJasmine Cha
Andrews University, Berrien Springs, MI
2 shared publicationsAllana Benjamin
Andrews University, Berrien Springs, MI
1 shared publicationBernhard Wernly
Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University Salzburg , Salzburg
1 shared publication
Latest Publications
- Open Access
- 29 May 2025
- Published by Frontiers Media SA in Frontiers in Health Services
- Vol. 5, 1404181
Strategies to improve recruitment to multicomponent group programs for overweight and obesity: a systematic review
Objective: Multicomponent programs are recommended for the treatment of children, adolescents, and adults with overweight or obesity. However, program providers often face difficulties reaching their target groups. This systematic review aimed at identifying recruitment strategies for multicomponent overweight and obesity programs in group settings and at summarizing barriers and facilitators for participation.Methods: We searched electronic databases (MEDLINE, CINAHL, The Cochrane Library, PsycInfo, Web of Science) and included primary studies reporting on recruitment strategies for multicomponent group programs for children, adolescents, and adults with overweight or obesity. All study designs were eligible for inclusion. Study characteristics, recruitment strategies as well as barriers and facilitators were extracted from the included articles, summarized in a table format, and synthesized narratively.Results: Of the 1,082 articles identified through the systematic literature search, 16 studies met the inclusion criteria and were included in the analysis. Eleven focused on children and adolescents, and five on adults. Recruitment strategies were categorized into active (e.g., referral by health professionals, direct contact) and passive methods (e.g., media advertising, flyers, posters). In most studies, a combination of several active and passive methods was applied or recommended. For socioeconomically disadvantaged groups, some targeted strategies were identified, e.g., recruitment in specific locations or through trained peers. Several possible barriers to recruitment were mentioned in the included studies, e.g., stigmatization, lack of time and resources of the healthcare staff, organizational barriers, lack of motivation of potential participants.Conclusion: This systematic review identified several active and passive strategies for recruiting children, adolescents, and adults with overweight and obesity into multicomponent group programs. The overview of possible recruitment methods is a valuable decision support to be used by program providers when designing new or adapting existing programs.
- 29 May 2025
- Published by Frontiers Media SA in Frontiers in Health Services
- Vol. 5, 1404181
Open AccessStrategies to improve recruitment to multicomponent group programs for overweight and obesity: a systematic review
Objective: Multicomponent programs are recommended for the treatment of children, adolescents, and adults with overweight or obesity. However, program providers often face difficulties reaching their target groups. This systematic review aimed at identifying recruitment strategies for multicomponent overweight and obesity programs in group settings and at summarizing barriers and facilitators for participation.Methods: We searched electronic databases (MEDLINE, CINAHL, The Cochrane Library, PsycInfo, Web of Science) and included primary studies reporting on recruitment strategies for multicomponent group programs for children, adolescents, and adults with overweight or obesity. All study designs were eligible for inclusion. Study characteristics, recruitment strategies as well as barriers and facilitators were extracted from the included articles, summarized in a table format, and synthesized narratively.Results: Of the 1,082 articles identified through the systematic literature search, 16 studies met the inclusion criteria and were included in the analysis. Eleven focused on children and adolescents, and five on adults. Recruitment strategies were categorized into active (e.g., referral by health professionals, direct contact) and passive methods (e.g., media advertising, flyers, posters). In most studies, a combination of several active and passive methods was applied or recommended. For socioeconomically disadvantaged groups, some targeted strategies were identified, e.g., recruitment in specific locations or through trained peers. Several possible barriers to recruitment were mentioned in the included studies, e.g., stigmatization, lack of time and resources of the healthcare staff, organizational barriers, lack of motivation of potential participants.Conclusion: This systematic review identified several active and passive strategies for recruiting children, adolescents, and adults with overweight and obesity into multicomponent group programs. The overview of possible recruitment methods is a valuable decision support to be used by program providers when designing new or adapting existing programs.
- Open Access
- 21 March 2024
- Published by Wiley in The Breast Journal
- Vol. 2024, 1-12
The Prognostic Quality of Risk Prediction Models to Assess the Individual Breast Cancer Risk in Women: An Overview of Reviews
Purpose. Breast cancer is the most common cancer among women globally, with an incidence of approximately two million cases in 2018. Organised age-based breast cancer screening programs were established worldwide to detect breast cancer earlier and to reduce mortality. Currently, there is substantial anticipation regarding risk-adjusted screening programs, considering various risk factors in addition to age. The present study investigated the discriminatory accuracy of breast cancer risk prediction models and whether they suit risk-based screening programs. Methods. Following the PICO scheme, we conducted an overview of reviews and systematically searched four databases. All methodological steps, including the literature selection, data extraction and synthesis, and the quality appraisal were conducted following the 4-eyes principle. For the quality assessment, the AMSTAR 2 tool was used. Results. We included eight systematic reviews out of 833 hits based on the prespecified inclusion criteria. The eight systematic reviews comprised ninety-nine primary studies that were also considered for the data analysis. Three systematic reviews were assessed as having a high risk of bias, while the others were rated with a moderate or low risk of bias. Most identified breast cancer risk prediction models showed a low prognostic quality. Adding breast density and genetic information as risk factors only moderately improved the models discriminatory accuracy. Conclusion. All breast cancer risk prediction models published to date show a limited ability to predict the individual breast cancer risk in women. Hence, it is too early to implement them in national breast cancer screening programs. Relevant randomised controlled trials about the benefit-harm ratio of risk-adjusted breast cancer screening programs compared to conventional age-based programs need to be awaited.
- 21 March 2024
- Published by Wiley in The Breast Journal
- Vol. 2024, 1-12
Open AccessThe Prognostic Quality of Risk Prediction Models to Assess the Individual Breast Cancer Risk in Women: An Overview of Reviews
Purpose. Breast cancer is the most common cancer among women globally, with an incidence of approximately two million cases in 2018. Organised age-based breast cancer screening programs were established worldwide to detect breast cancer earlier and to reduce mortality. Currently, there is substantial anticipation regarding risk-adjusted screening programs, considering various risk factors in addition to age. The present study investigated the discriminatory accuracy of breast cancer risk prediction models and whether they suit risk-based screening programs. Methods. Following the PICO scheme, we conducted an overview of reviews and systematically searched four databases. All methodological steps, including the literature selection, data extraction and synthesis, and the quality appraisal were conducted following the 4-eyes principle. For the quality assessment, the AMSTAR 2 tool was used. Results. We included eight systematic reviews out of 833 hits based on the prespecified inclusion criteria. The eight systematic reviews comprised ninety-nine primary studies that were also considered for the data analysis. Three systematic reviews were assessed as having a high risk of bias, while the others were rated with a moderate or low risk of bias. Most identified breast cancer risk prediction models showed a low prognostic quality. Adding breast density and genetic information as risk factors only moderately improved the models discriminatory accuracy. Conclusion. All breast cancer risk prediction models published to date show a limited ability to predict the individual breast cancer risk in women. Hence, it is too early to implement them in national breast cancer screening programs. Relevant randomised controlled trials about the benefit-harm ratio of risk-adjusted breast cancer screening programs compared to conventional age-based programs need to be awaited.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 2540
Abstract 2540: Modulation of apoptosis in pancreatic adenocarcinoma BxPC-3 cells and ductal carcinoma PANC-1 cells by aqueous extract of Bryophyllum pinnatum
Bryophyllum pinnatum (BP) has been widely used in tropical regions as traditional medicine. It is reported to have antioxidant, immunomodulatory, antidiabetic, anti-inflammatory, antihypertensive, wound healing, cytotoxic, and antitumor-promoting activities. Its major secondary metabolites include bufadienolides, flavonoids, triterpenes, and steroids. Pancreatic cancer is usually symptom-free during development and is advanced by the time of diagnosis with a poor prognosis. BxPC-3 is a pancreatic adenocarcinoma cell derived from a 61-year-old female with adenocarcinoma while PANC-1 is a pancreatic ductal carcinoma cell derived from a 56-year-old male with adenocarcinoma in the head of the pancreas and metastasized to the duodenal wall. Apoptosis is a controlled program cell death process that the body uses to combat cancer development. We previously showed that an aqueous extract of BP effectively modulated apoptosis in glioblastoma U-87 MG brain cancer cells. It also induced apoptosis in colon HCT 116 cancer cells but not in colon CCD 841 CoN normal epithelial cells by modulating the pro-apoptotic and anti-apoptotic proteins. In this study, we used the green/red/blue fluorescent Apoptosis/Necrosis Detection Kit and the Human Apoptosis Antibody Array - Membrane [43 Targets] Test (Abcam) to assess the effect of BP in the induction and modulation of apoptosis on BxPC-3 and PANC-1 cells. Our fluorescent apoptosis data showed that a 2-hour treatment with 1.5 mg and 3.0 mg aqueous extract of BP induced a statistically significant percentage of apoptosis in BxPC-3 and PANC-1 cells (74.0 ± 1.0%, 90.0 ± 1.0% > 14.0% ± 4.0%, p < 0.05; 85.0 ± 3.0%, 96.5 ± 0.5% > 11.5%± 3.5%, p < 0.05) as compared to the negative control respectively. Similar results were obtained with the 4-hour incubation period (57.0 ± 1.0%, 78.5 ± 6.5% > 9.5% ± 2.5%, p < 0.05; 89.0 ± 1.0%, 85.5 ± 5.5% > 18.2% ± 2.0%, p < 0.05). From the antibody array-membrane experiments, modulation of various apoptosis markers by BP such as the pro-apoptotic proteins Bad, Bax, p27, and p53 as compared to the negative controls were revealed; and regulation of anti-apoptotic proteins Bcl-2, IGF-I, and p21 were also observed. These results suggest that BP contains phytochemicals that induce apoptosis in pancreatic adenocarcinoma BxPC-3 and PANC-1 cells via the modulation of various apoptotic protein productions. Further study of their specific modulation effects of apoptosis is warranted to reveal the potential chemopreventive and therapeutic properties of BP against pancreatic cancer. Citation Format: Jasmine Cha, Elim Choi, Jessica Yi, Sarah Wolf, Rekha Isaac, Min S. Kang, Allana Benjamin, Christine Choi, Ryan Hayes, Brian Yuen Yau Wong. Modulation of apoptosis in pancreatic adenocarcinoma BxPC-3 cells and ductal carcinoma PANC-1 cells by aqueous extract of Bryophyllum pinnatum [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2540.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 2540
Abstract 2540: Modulation of apoptosis in pancreatic adenocarcinoma BxPC-3 cells and ductal carcinoma PANC-1 cells by aqueous extract of Bryophyllum pinnatum
Bryophyllum pinnatum (BP) has been widely used in tropical regions as traditional medicine. It is reported to have antioxidant, immunomodulatory, antidiabetic, anti-inflammatory, antihypertensive, wound healing, cytotoxic, and antitumor-promoting activities. Its major secondary metabolites include bufadienolides, flavonoids, triterpenes, and steroids. Pancreatic cancer is usually symptom-free during development and is advanced by the time of diagnosis with a poor prognosis. BxPC-3 is a pancreatic adenocarcinoma cell derived from a 61-year-old female with adenocarcinoma while PANC-1 is a pancreatic ductal carcinoma cell derived from a 56-year-old male with adenocarcinoma in the head of the pancreas and metastasized to the duodenal wall. Apoptosis is a controlled program cell death process that the body uses to combat cancer development. We previously showed that an aqueous extract of BP effectively modulated apoptosis in glioblastoma U-87 MG brain cancer cells. It also induced apoptosis in colon HCT 116 cancer cells but not in colon CCD 841 CoN normal epithelial cells by modulating the pro-apoptotic and anti-apoptotic proteins. In this study, we used the green/red/blue fluorescent Apoptosis/Necrosis Detection Kit and the Human Apoptosis Antibody Array - Membrane [43 Targets] Test (Abcam) to assess the effect of BP in the induction and modulation of apoptosis on BxPC-3 and PANC-1 cells. Our fluorescent apoptosis data showed that a 2-hour treatment with 1.5 mg and 3.0 mg aqueous extract of BP induced a statistically significant percentage of apoptosis in BxPC-3 and PANC-1 cells (74.0 ± 1.0%, 90.0 ± 1.0% > 14.0% ± 4.0%, p < 0.05; 85.0 ± 3.0%, 96.5 ± 0.5% > 11.5%± 3.5%, p < 0.05) as compared to the negative control respectively. Similar results were obtained with the 4-hour incubation period (57.0 ± 1.0%, 78.5 ± 6.5% > 9.5% ± 2.5%, p < 0.05; 89.0 ± 1.0%, 85.5 ± 5.5% > 18.2% ± 2.0%, p < 0.05). From the antibody array-membrane experiments, modulation of various apoptosis markers by BP such as the pro-apoptotic proteins Bad, Bax, p27, and p53 as compared to the negative controls were revealed; and regulation of anti-apoptotic proteins Bcl-2, IGF-I, and p21 were also observed. These results suggest that BP contains phytochemicals that induce apoptosis in pancreatic adenocarcinoma BxPC-3 and PANC-1 cells via the modulation of various apoptotic protein productions. Further study of their specific modulation effects of apoptosis is warranted to reveal the potential chemopreventive and therapeutic properties of BP against pancreatic cancer. Citation Format: Jasmine Cha, Elim Choi, Jessica Yi, Sarah Wolf, Rekha Isaac, Min S. Kang, Allana Benjamin, Christine Choi, Ryan Hayes, Brian Yuen Yau Wong. Modulation of apoptosis in pancreatic adenocarcinoma BxPC-3 cells and ductal carcinoma PANC-1 cells by aqueous extract of Bryophyllum pinnatum [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2540.
- Open Access
- 29 November 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (2) , 808-823
Subcutaneous Implantable Cardioverter-Defibrillator: A Systematic Review of Comparative Effectiveness and Safety
This systematic review evaluated the clinical effectiveness and safety of subcutaneous implantable cardioverter-defibrillator (S-ICD) in patients at an increased risk of sudden cardiac death and with an ICD indication for primary or secondary prevention. A systematic literature search was conducted in four databases (Medline via Ovid, Embase, the Cochrane Library, and HTA-INAHTA). Randomized controlled trials (RCTs) and controlled observational studies with ≥100 S-ICD patients and a low to moderate risk of bias were eligible for inclusion. The studies' quality and the available evidence's strength were assessed using the Cochrane risk of bias tool, the ROBINS-I tool, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. One RCT, a post hoc analysis of the RCT (n = 849) and four controlled observational studies (n = 7149) were included. The quality of the available evidence was graded as low to very low, except for the primary composite endpoint of the RCT, which was rated as moderate quality. After 4 years, the RCT showed that S-ICD was non-inferior to TV-ICD regarding the composite endpoint of inappropriate shocks and device-related complications (68 [15.1%] vs. 68 [15.7%], hazard ratio [HR] 0.99, 95% confidence interval [CI] [0.71, 1.39], non-inferiority margin 1.45, P = 0.001). The RCT and two observational studies reported statistically significantly fewer lead complications in S-ICD patients (after 4 years: 1.4% vs. 6.6%, HR 0.24, 95% CI [0.10, 0.54]; after 3 years: 0.3% vs. 2.3%, P = 0.03; and after 5 years: 0.8% vs. 11.5%, P = 0.03). Identified evidence about appropriate and inappropriate shocks was inconclusive: The RCT detected statistically significantly more appropriate shocks in patients with S-ICD (83 [19.2%] vs. 57 [11.5%], HR 1.52, 95% CI [1.08, 2.12], P = 0.02), whereas one observational study showed a statistically significantly lower rate in the S-ICD group (9.9%, 95% CI [7.0, 13.9], vs. 13.9%, 95% CI [10.8, 17.8], P = 0.003). Regarding inappropriate shocks, one observational study reported statistically significantly higher rates in the S-ICD cohort (11.9% vs. 7.5%, P = 0.007), whereas the RCT and two other observational studies did not detect a statistically significant difference between the treatment groups (P > 0.05). None of the included studies showed a statistically significant difference in overall mortality and shock efficacy between patients with S-ICD and TV-ICD (P > 0.05). The available evidence is insufficient to show the superiority of S-ICD compared with TV-ICD, hindering the widespread use of the technology. Results of the recently completed ATLAS trial are to be awaited, and the anticipated role of the S-ICD needs to be clearly formulated.
- 29 November 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (2) , 808-823
Open AccessSubcutaneous Implantable Cardioverter-Defibrillator: A Systematic Review of Comparative Effectiveness and Safety
This systematic review evaluated the clinical effectiveness and safety of subcutaneous implantable cardioverter-defibrillator (S-ICD) in patients at an increased risk of sudden cardiac death and with an ICD indication for primary or secondary prevention. A systematic literature search was conducted in four databases (Medline via Ovid, Embase, the Cochrane Library, and HTA-INAHTA). Randomized controlled trials (RCTs) and controlled observational studies with ≥100 S-ICD patients and a low to moderate risk of bias were eligible for inclusion. The studies' quality and the available evidence's strength were assessed using the Cochrane risk of bias tool, the ROBINS-I tool, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. One RCT, a post hoc analysis of the RCT (n = 849) and four controlled observational studies (n = 7149) were included. The quality of the available evidence was graded as low to very low, except for the primary composite endpoint of the RCT, which was rated as moderate quality. After 4 years, the RCT showed that S-ICD was non-inferior to TV-ICD regarding the composite endpoint of inappropriate shocks and device-related complications (68 [15.1%] vs. 68 [15.7%], hazard ratio [HR] 0.99, 95% confidence interval [CI] [0.71, 1.39], non-inferiority margin 1.45, P = 0.001). The RCT and two observational studies reported statistically significantly fewer lead complications in S-ICD patients (after 4 years: 1.4% vs. 6.6%, HR 0.24, 95% CI [0.10, 0.54]; after 3 years: 0.3% vs. 2.3%, P = 0.03; and after 5 years: 0.8% vs. 11.5%, P = 0.03). Identified evidence about appropriate and inappropriate shocks was inconclusive: The RCT detected statistically significantly more appropriate shocks in patients with S-ICD (83 [19.2%] vs. 57 [11.5%], HR 1.52, 95% CI [1.08, 2.12], P = 0.02), whereas one observational study showed a statistically significantly lower rate in the S-ICD group (9.9%, 95% CI [7.0, 13.9], vs. 13.9%, 95% CI [10.8, 17.8], P = 0.003). Regarding inappropriate shocks, one observational study reported statistically significantly higher rates in the S-ICD cohort (11.9% vs. 7.5%, P = 0.007), whereas the RCT and two other observational studies did not detect a statistically significant difference between the treatment groups (P > 0.05). None of the included studies showed a statistically significant difference in overall mortality and shock efficacy between patients with S-ICD and TV-ICD (P > 0.05). The available evidence is insufficient to show the superiority of S-ICD compared with TV-ICD, hindering the widespread use of the technology. Results of the recently completed ATLAS trial are to be awaited, and the anticipated role of the S-ICD needs to be clearly formulated.
- Open Access
- 23 August 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-11
Possible long COVID healthcare pathways: a scoping review
Background: Individuals of all ages and with all degrees of severity of the coronavirus disease (COVID) can suffer from persisting or reappearing symptoms called long COVID. Long COVID involves various symptoms, such as shortness of breath, fatigue, or organ damage. The growing number of long COVID cases places a burden on the patients and the broader economy and, hence, has gained more weight in political decisions. This scoping review aimed to give an overview of recommendations about possible long COVID healthcare pathways and requirements regarding decision-making and communication for healthcare professionals. Methods: A systematic search in four databases and biweekly update-hand searches were conducted. In addition to guidelines and reviews, expert opinions in consensus statements or clinical perspectives were also considered. Data were systematically extracted and subsequently narratively and graphically summarised. Results: Fourteen references, five guidelines, four reviews, one consensus paper, and four clinical perspectives were included. The evidence recommended that most long COVID-related healthcare should be in primary care. Patients with complex symptoms should be referred to specialized long COVID outpatient assessment clinics. In contrast, patients with one dominant symptom should be directed to the respective specialist for a second assessment. Depending on the patients’ needs, further referral options include, e.g. rehabilitation or non-medical health services. Self-management and good communication between healthcare professionals and patients are crucial aspects of the long COVID management recommendations. Conclusions: The quality of the included guidelines and reviews is limited in the methods applied due to the novelty of this topic and the associated urgency for research. Hence, an update review with more rigorous data is recommended. Furthermore, the systematic collection of real-world data on long COVID surveillance needs to be set up soon to gather further information on the duration and severity of long COVID and thereby facilitate long COVID care planning.
- 23 August 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-11
Open AccessPossible long COVID healthcare pathways: a scoping review
Background: Individuals of all ages and with all degrees of severity of the coronavirus disease (COVID) can suffer from persisting or reappearing symptoms called long COVID. Long COVID involves various symptoms, such as shortness of breath, fatigue, or organ damage. The growing number of long COVID cases places a burden on the patients and the broader economy and, hence, has gained more weight in political decisions. This scoping review aimed to give an overview of recommendations about possible long COVID healthcare pathways and requirements regarding decision-making and communication for healthcare professionals. Methods: A systematic search in four databases and biweekly update-hand searches were conducted. In addition to guidelines and reviews, expert opinions in consensus statements or clinical perspectives were also considered. Data were systematically extracted and subsequently narratively and graphically summarised. Results: Fourteen references, five guidelines, four reviews, one consensus paper, and four clinical perspectives were included. The evidence recommended that most long COVID-related healthcare should be in primary care. Patients with complex symptoms should be referred to specialized long COVID outpatient assessment clinics. In contrast, patients with one dominant symptom should be directed to the respective specialist for a second assessment. Depending on the patients’ needs, further referral options include, e.g. rehabilitation or non-medical health services. Self-management and good communication between healthcare professionals and patients are crucial aspects of the long COVID management recommendations. Conclusions: The quality of the included guidelines and reviews is limited in the methods applied due to the novelty of this topic and the associated urgency for research. Hence, an update review with more rigorous data is recommended. Furthermore, the systematic collection of real-world data on long COVID surveillance needs to be set up soon to gather further information on the duration and severity of long COVID and thereby facilitate long COVID care planning.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6261A
Abstract 6261A: Chinese medicinal herbs Scutellaria barbata and Oldenlandia diffusa modulate apoptosis via induction of pro-apoptotic and anti-apoptotic proteins in MDA-MB-157 and 93B breast cancer cells
Scutellaria barbata (SB) and Oldenlandia diffusa (OD) have been used in Traditional Chinese Medicine for treating colon cancer, glioblastoma, and ovarian cancer liver, lung, and rectal cancers. These two herbs are included in most of the herbal cancer treatment formulas in China and Taiwan hospitals. We previously demonstrated that aqueous extracts of SB and OD inhibited mutagenesis, DNA binding, and metabolism of aflatoxin B1 and benzo[a]pyrene in carcinogenesis. In studies by Hugo (2006) and Perez (2010), the efficacy of BZL 101 (an extract of SB) has been demonstrated in preliminary Phase Ia and Ib clinical trials in metastatic breast cancer patients. It is also shown to induce an S phase arrest of the cell cycle by affecting the Cycline A2 and CDK2 expression in estrogen-sensitive MCF7 and estrogen insensitive MDA-MB-231 breast cancer cells. MeOH and BuOH extract of OD have been illustrated to reduce MCF7 invasion via the inhibition of MMP-9 and ICAM-1 apoptotic proteins expression. Ursolic acid of OD could inhibit breast cancer metastasis by suppressing glycolytic metabolism through activating SP1/Caveolin-1 signaling. In this study, the effectiveness of aqueous extract of SB and OD in the modulation of apoptosis of breast cancer cell lines MDA-MB-157 and 93B (a drug-resistant APC-mutant of it) were investigated. Assessments were performed using green/red/blue fluorescent Apoptosis/Necrosis Detection Test and the Human Apoptosis Antibody Array - Membrane [43 Targets] Test (Abcam). Our fluorescent apoptosis data showed that 3-hours treatment with 2.5 mg aqueous extract of SB induced a statistically significant percentage of apoptosis in MDA-MB-157 (46.5 ± 7.5% > 16%± 1.0%, p < 0.05) and 93B (46.5 ± 7.5% > 16%± 1.0%, p < 0.05) as compared to the negative control. Similar results were obtained with the OD treatment. From the antibody array-membrane experiments, modulation of various apoptosis markers by SB such as the pro-apoptotic proteins BID and BIM (p=0.019; p=0.007) in MDA-MB-157 and Bad (p=0.002), Bax (p=0.020), BID (p=0.001), p27 (p=0.004), p53 (p=0.022) in 93B as compared to the negative controls; and anti-apoptotic markers BcL-2, FasL, IGF-I, and p21 were also observed. OD treatment also induced similar significant production of these two types of proteins. These results suggest that SB and OD contain phytochemicals that induce apoptosis in MDA-MB-157 and 93B via the modulation of these pro-apoptotic and anti-apoptotic proteins. Citation Format: MinSeo Kang, Nathaly Manrique, Rekha Issac, Sarah Wolf, Jasmine Cha, SungBeen Han, Hugo Jie Qin, Lun Kim, Padma P. Uppala, Brian Yuen Yau Wong. Chinese medicinal herbs Scutellaria barbata and Oldenlandia diffusa modulate apoptosis via induction of pro-apoptotic and anti-apoptotic proteins in MDA-MB-157 and 93B breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6261A.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6261A
Open AccessAbstract 6261A: Chinese medicinal herbs Scutellaria barbata and Oldenlandia diffusa modulate apoptosis via induction of pro-apoptotic and anti-apoptotic proteins in MDA-MB-157 and 93B breast cancer cells
Scutellaria barbata (SB) and Oldenlandia diffusa (OD) have been used in Traditional Chinese Medicine for treating colon cancer, glioblastoma, and ovarian cancer liver, lung, and rectal cancers. These two herbs are included in most of the herbal cancer treatment formulas in China and Taiwan hospitals. We previously demonstrated that aqueous extracts of SB and OD inhibited mutagenesis, DNA binding, and metabolism of aflatoxin B1 and benzo[a]pyrene in carcinogenesis. In studies by Hugo (2006) and Perez (2010), the efficacy of BZL 101 (an extract of SB) has been demonstrated in preliminary Phase Ia and Ib clinical trials in metastatic breast cancer patients. It is also shown to induce an S phase arrest of the cell cycle by affecting the Cycline A2 and CDK2 expression in estrogen-sensitive MCF7 and estrogen insensitive MDA-MB-231 breast cancer cells. MeOH and BuOH extract of OD have been illustrated to reduce MCF7 invasion via the inhibition of MMP-9 and ICAM-1 apoptotic proteins expression. Ursolic acid of OD could inhibit breast cancer metastasis by suppressing glycolytic metabolism through activating SP1/Caveolin-1 signaling. In this study, the effectiveness of aqueous extract of SB and OD in the modulation of apoptosis of breast cancer cell lines MDA-MB-157 and 93B (a drug-resistant APC-mutant of it) were investigated. Assessments were performed using green/red/blue fluorescent Apoptosis/Necrosis Detection Test and the Human Apoptosis Antibody Array - Membrane [43 Targets] Test (Abcam). Our fluorescent apoptosis data showed that 3-hours treatment with 2.5 mg aqueous extract of SB induced a statistically significant percentage of apoptosis in MDA-MB-157 (46.5 ± 7.5% > 16%± 1.0%, p < 0.05) and 93B (46.5 ± 7.5% > 16%± 1.0%, p < 0.05) as compared to the negative control. Similar results were obtained with the OD treatment. From the antibody array-membrane experiments, modulation of various apoptosis markers by SB such as the pro-apoptotic proteins BID and BIM (p=0.019; p=0.007) in MDA-MB-157 and Bad (p=0.002), Bax (p=0.020), BID (p=0.001), p27 (p=0.004), p53 (p=0.022) in 93B as compared to the negative controls; and anti-apoptotic markers BcL-2, FasL, IGF-I, and p21 were also observed. OD treatment also induced similar significant production of these two types of proteins. These results suggest that SB and OD contain phytochemicals that induce apoptosis in MDA-MB-157 and 93B via the modulation of these pro-apoptotic and anti-apoptotic proteins. Citation Format: MinSeo Kang, Nathaly Manrique, Rekha Issac, Sarah Wolf, Jasmine Cha, SungBeen Han, Hugo Jie Qin, Lun Kim, Padma P. Uppala, Brian Yuen Yau Wong. Chinese medicinal herbs Scutellaria barbata and Oldenlandia diffusa modulate apoptosis via induction of pro-apoptotic and anti-apoptotic proteins in MDA-MB-157 and 93B breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6261A.
- 26 October 2021
- Published by Springer Nature in neuropsychiatrie
- Vol. 36 (1) , 28-39
Integrating home treatment into the Austrian child and adolescent mental health care system: an implementation science perspective
Summary Background In Austria, similar to other countries, health care planners have considered implementing home treatment (HT) programs for children and adolescents with mental health problems. However, introducing any new service innovation into the complex environment of the child and adolescent mental health care system requires context and implementation issues to be taken into account in advance. Methods We identified implementation themes from international HT models and developed a questionnaire with open-ended implementation-related questions for Austrian professionals. We analysed the qualitative results alongside the domains in the Context and Implementation of Complex Interventions (CICI) framework to detect key implementation challenges for HT in Austria. Results We found six implementation themes in international HT models, which formed the basis for development of the questionnaire. Within the qualitative data from ten Austrian professionals who responded to the questionnaire, we identified implementation challenges in all eight context and all four implementation domains of the CICI framework. Conclusions Key implementation challenges detected highlight the need to address the fit of HT within existing sociocultural norms and limited available human resources. Regional context-specific solutions need to be found on how to embed this new element best into the existing provider and financing structures. This calls for monitoring and evaluation alongside implementation to support decision-making.
- 26 October 2021
- Published by Springer Nature in neuropsychiatrie
- Vol. 36 (1) , 28-39
Integrating home treatment into the Austrian child and adolescent mental health care system: an implementation science perspective
Summary Background In Austria, similar to other countries, health care planners have considered implementing home treatment (HT) programs for children and adolescents with mental health problems. However, introducing any new service innovation into the complex environment of the child and adolescent mental health care system requires context and implementation issues to be taken into account in advance. Methods We identified implementation themes from international HT models and developed a questionnaire with open-ended implementation-related questions for Austrian professionals. We analysed the qualitative results alongside the domains in the Context and Implementation of Complex Interventions (CICI) framework to detect key implementation challenges for HT in Austria. Results We found six implementation themes in international HT models, which formed the basis for development of the questionnaire. Within the qualitative data from ten Austrian professionals who responded to the questionnaire, we identified implementation challenges in all eight context and all four implementation domains of the CICI framework. Conclusions Key implementation challenges detected highlight the need to address the fit of HT within existing sociocultural norms and limited available human resources. Regional context-specific solutions need to be found on how to embed this new element best into the existing provider and financing structures. This calls for monitoring and evaluation alongside implementation to support decision-making.
- Open Access
- 1 October 2021
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 31 (Supplement)
Effectiveness and safety analysis of home-treatment models in child and adolescent psychiatric care
Background: The Austrian child and adolescent psychiatric care landscape is characterised by substantial deficits on the intramural and extramural level. To overcome these supply shortfalls alternative outreach approaches, such as home-treatment (HT) can be introduced, which shall facilitate the reduction of hospitalisations. Thus, we aimed to systematically characterise international HT models considering their efficacy and safety in the area of child and adolescent psychiatry. Methods: A systematic literature search in six databases, as well as an extended hand search, was conducted. Taking into account the predefined inclusion criteria, six HT studies were eligible for the qualitative synthesis; comprising two randomised controlled trials (RCTs), two non-randomised controlled trials (NRCTs) and two observational studies. Results: The following four effectiveness measures were investigated: change in symptoms, hospitalisation, treatment satisfaction and need for further treatment. A benefit of HT models compared to stationary care could be identified considering patient symptoms, espeicially psychopathological symptoms; however, solely in the longer-term treatment. Studies have also shown that HT is associated with fewer days of hospitalisation, but with a higher need for further treatments. Inconclusive evidence was identified considering treatment satisfaction. Safety endpoints were not evaluated by any included study. Conclusions: The results are limited by a moderate to high risk of bias due to several factors (e.g. small sample sizes, various assessment instruments). However, the evidence indicates that in long-term, HT can lead to an improvement in psychopathological symptoms and supports the transition from inpatient to outpatient care. Therefore, HT may be considered as an alternative or supplement to the stationary child and adolescent psychiatric care. However, further evidence is needed considering safety outcomes. Key messages: In the long-term, home-treatment can lead to a bigger improvement in psychopathological symptoms for the children and adolescent compared to stationary care. Further evidence is needed especially regarding possible adverse events of home-treatment in the field of child and adolescent psychiatry.
- 1 October 2021
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 31 (Supplement)
Open AccessEffectiveness and safety analysis of home-treatment models in child and adolescent psychiatric care
Background: The Austrian child and adolescent psychiatric care landscape is characterised by substantial deficits on the intramural and extramural level. To overcome these supply shortfalls alternative outreach approaches, such as home-treatment (HT) can be introduced, which shall facilitate the reduction of hospitalisations. Thus, we aimed to systematically characterise international HT models considering their efficacy and safety in the area of child and adolescent psychiatry. Methods: A systematic literature search in six databases, as well as an extended hand search, was conducted. Taking into account the predefined inclusion criteria, six HT studies were eligible for the qualitative synthesis; comprising two randomised controlled trials (RCTs), two non-randomised controlled trials (NRCTs) and two observational studies. Results: The following four effectiveness measures were investigated: change in symptoms, hospitalisation, treatment satisfaction and need for further treatment. A benefit of HT models compared to stationary care could be identified considering patient symptoms, espeicially psychopathological symptoms; however, solely in the longer-term treatment. Studies have also shown that HT is associated with fewer days of hospitalisation, but with a higher need for further treatments. Inconclusive evidence was identified considering treatment satisfaction. Safety endpoints were not evaluated by any included study. Conclusions: The results are limited by a moderate to high risk of bias due to several factors (e.g. small sample sizes, various assessment instruments). However, the evidence indicates that in long-term, HT can lead to an improvement in psychopathological symptoms and supports the transition from inpatient to outpatient care. Therefore, HT may be considered as an alternative or supplement to the stationary child and adolescent psychiatric care. However, further evidence is needed considering safety outcomes. Key messages: In the long-term, home-treatment can lead to a bigger improvement in psychopathological symptoms for the children and adolescent compared to stationary care. Further evidence is needed especially regarding possible adverse events of home-treatment in the field of child and adolescent psychiatry.
- 1 January 2021
- Published by Springer Nature in Qualitas
- Vol. 20 (1) , 38
Home-Treatment in der Kinderund Jugendpsychiatrie
- 1 January 2021
- Published by Springer Nature in Qualitas
- Vol. 20 (1) , 38
Home-Treatment in der Kinderund Jugendpsychiatrie
- 25 June 2020
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 232 (04) , 187-196
A systematic Analysis of Evaluation Methods for Inpatient Children and Adolescents Rehabilitation Programs
Increasing chronic diseases in children and adolescents such as obesity, asthma bronchiale, or mental disorders, result in a growing importance of rehabilitation programs and subsequent program evaluations. We conducted a systematic literature search in 5 databases and provided an overview of methods for evaluating inpatient child and adolescent rehabilitation programs. This included an identification of generic and indication-specific outcomes and standardized measuring instruments. Eighteen studies covering 8 indication groups were considered for the qualitative analysis according to the pre-defined inclusion and exclusion criteria. Overall, the 18 studies included eight generic outcomes: (1) quality of life, (2) psychological well-being, (3) perceived changes, (4) functionality, (5) rehabilitation satisfaction, (6) self-management/-efficacy, (7) days of absence and (8) self-esteem. Eighteen standardized measuring instruments and 6 self-developed questionnaires were used to assess the 8 generic outcomes. Besides, indication-specific outcomes for 5 indications namely traumatic brain injury, obesity, diabetes, eating disorders and neurodermatitis, were reported. Overall, the present systematic review summarizes essential content (8 generic outcomes) and methods for evaluations of children and adolescent rehabilitation programs; however, before choosing a generic measuring tool during an evaluation, the psychometric validity of the instruments should be evaluated. In addition to the generic perspective, the evaluation of disease-specific outcomes is recommended.
- 25 June 2020
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 232 (04) , 187-196
A systematic Analysis of Evaluation Methods for Inpatient Children and Adolescents Rehabilitation Programs
Increasing chronic diseases in children and adolescents such as obesity, asthma bronchiale, or mental disorders, result in a growing importance of rehabilitation programs and subsequent program evaluations. We conducted a systematic literature search in 5 databases and provided an overview of methods for evaluating inpatient child and adolescent rehabilitation programs. This included an identification of generic and indication-specific outcomes and standardized measuring instruments. Eighteen studies covering 8 indication groups were considered for the qualitative analysis according to the pre-defined inclusion and exclusion criteria. Overall, the 18 studies included eight generic outcomes: (1) quality of life, (2) psychological well-being, (3) perceived changes, (4) functionality, (5) rehabilitation satisfaction, (6) self-management/-efficacy, (7) days of absence and (8) self-esteem. Eighteen standardized measuring instruments and 6 self-developed questionnaires were used to assess the 8 generic outcomes. Besides, indication-specific outcomes for 5 indications namely traumatic brain injury, obesity, diabetes, eating disorders and neurodermatitis, were reported. Overall, the present systematic review summarizes essential content (8 generic outcomes) and methods for evaluations of children and adolescent rehabilitation programs; however, before choosing a generic measuring tool during an evaluation, the psychometric validity of the instruments should be evaluated. In addition to the generic perspective, the evaluation of disease-specific outcomes is recommended.